9 Meters Biopharma announced receipt of a written response from the U.S. Food and Drug Administration on the request for a Type B pre-IND meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136 in the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NMTR:
- 9 Meters Biopharma expects cash to fund programs into 3Q23
- 9 Meters Biopharma reports Q4 EPS (92c), consensus (76c)
- 9 Meters Biopharma cut to Hold at Truist on cash overhang, lack of catalysts
- 9 Meters Biopharma downgraded to Hold from Buy at Truist
- 9 Meters Biopharma price target lowered to $1.70 from $2.70 at Citi